Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant. A retrospective study from the CMWP (Chronic Malignancies Working Party) of the EBMT
Myelodysplastic syndromes (MDS) mostly affect elderly patients with a median age at diagnosis of 74 years [1 –3]. The International Prognosis Scoring System (IPSS) prognostic classification reflects the heterogeneous clinical course of MDS and may be used to guide therapeutic decisions [4]. Supportive care with transfusions and erythropoietin stimulating agents may compensate cytopenia in patients with l ow risk disease. On the other hand, the treatment of high risk MDS aims at postponing its progression to acute leukemia, e.g.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Martin Carr é, Raphaël Porcher, Jürgen Finke, Gerhard Ehninger, Linda Koster, Dietrich Beelen, Arnold Ganser, Liisa Volin, Sara Lozano, Lone Friis, Mauricette Michallet, Johanna Tischer, Eduardo Olavarria, Maria Jesús Pascual Cascon, Simona Iacobelli, Source Type: research
More News: Acute Leukemia | Biology | Cancer & Oncology | Chronic Leukemia | Hematology | Leukemia | Myelodysplastic Syndrome | Nutrition | Study | Transplants